EFFECTS OF PHYSOSTIGMINE ON RAT BRAIN ACETYLCHOLINE, ACETYLCHOLINESTERASE AND CONDITIONED POLE JUMPING*†

JOHN A. ROSECRANS‡, ANTHONY T. DREN§, and EDWARD F. DOMINO
Department of Pharmacology, Univ. of Michigan, Ann Arbor, Michigan

(Accepted 20 July 1967)

Summary—The present study was designed to provide evidence that the behavioral effects of physostigmine are related to inhibition of brain acetylcholinesterase (AChE). Adult male Holtzman rats were trained to pole jump to a buzzer as the conditioned stimulus and to electric shock to the grid floor as the unconditioned stimulus. All drugs were given s.c. as base. Physostigmine (0.125-0.25 mg/kg) depressed pole jump behavior in methyl atropine (2.1 mg/kg) or saline-treated rats. (−) Hyoscyamine (1 mg/kg) blocked the actions of physostigmine, suggesting a central site of action.

Total brain acetylcholine (ACh) and AChE were determined in various groups of animals. The increase in brain ACh and the decrease in AChE activity were negatively correlated in physostigmine-treated rats. These changes were highly correlated during the onset and peak of physostigmine behavioral effects but not during the recovery period. Although (−) hyoscyamine antagonized the behavioral effects of physostigmine, it did not alter the increase in brain ACh or decrease in brain AChE. It is concluded that most of the behavioral effects of physostigmine are related to central AChE inhibition.

INTRODUCTION

One of the most important tasks of the neuropharmacologist is to correlate the behavioral effects of centrally acting drugs with their biochemical actions. Physostigmine is a drug well suited for such studies because its neurochemical effects are well documented and easily measured. Its relatively rapid onset and short duration of action make it especially desirable. This reversible cholinesterase inhibitor has been used successfully to study central cholinergic mechanisms and their relationship to behavior. PFEIFFER and JENNY (1957) observed that physostigmine was a potent depressant of learned behavior (pole-jump response). They ascribed its site of action to the central nervous system since physostigmine-induced behavioral depression was prevented by atropine pretreatment, whereas methyl atropine offered little protection. GOLDBERG et al. (1963, 1965) attempted to correlate rat brain cholinesterase activity with inhibition of discrete shock avoidance behavior produced by three different anticholinesterases. The compounds studied included: 3-iso-propylphenyl carbamate (compound 10854), naphthyl N-methyl carbamate (carbaryl) and physostigmine. These investigators obtained a correlation between the behavioral

*Supported in part by the Michigan Neuropsychopharmacology Research Program, USPHS, Grant MH-11846-01
‡Postdoctoral Fellow NIH, MH-10,570-02. Present address: Department of Pharmacology, Medical College of Virginia, Richmond, Virginia.
§Present address: Department of Pharmacology, Abbott Laboratories, North Chicago, Illinois.
depression produced by increasing doses of these drugs and inhibition of brain cholinesterase. However, at equipotent anticholinesterase inhibiting doses, a greater behavioral depressant effect was observed with physostigmine and carbaryl than compound 10854. Atropine sulfate significantly blocked the behavioral effects produced by all three agents. On the basis of these studies, GOLDBERG et al. (1963, 1965) concluded that physostigmine and carbaryl had a direct cholinergic agonist component which was not as prominent with compound 10854.

The present investigation was designed to provide further evidence that the behavioral effects of physostigmine are related to its actions as a cholinesterase inhibitor. Both brain acetylcholine (ACh) and acetylcholinesterase (AChE) activity were measured and compared to the behavioral deficits produced by physostigmine in methyl atropine and (−) hyoscymamine-pretreated animals.

METHODS

Holtzman male albino rats, 90–120 days old, were utilized throughout this investigation. The drugs were dissolved in saline solution and administered s.c. All drug dosage was calculated as base.

Behavioral procedures. Twenty-four animals were trained to acquire the pole jump response of COOK and WEIDLEY (1957) as modified by MEYERS et al. (1964). The conditioned stimulus (CS), a buzzer, was presented for 5 sec and overlapped 5 sec with an unconditioned stimulus (US), a 1.0 mA, 60 c/s shock, scrambled through the grid floor. An avoidance response was defined as a pole jump to the CS. An escape response was defined as a pole jump to the US. Inter-trial intervals ranged from 20 to 40 sec with an average of 30 sec. Trials were given in blocks of 10 with 1 min between trial blocks. Animals usually attained a 90% criterion within 100 trials which represented two experimental sessions of 50 trials each. Before any drugs were administered, each animal completed 15 to 18 such experimental sessions. This amounted to 3 sessions per week for 5–6 consecutive weeks. Such animals showed 100% avoidance behavior and therefore were highly overtrained.

After reaching a stable behavioral baseline each animal was pretreated with saline solution, atropine methyl nitrate (2.1 mg/kg) or various doses of (−) hyoscymamine (0.086 to 1.0 mg/kg) 30 min prior to the administration of physostigmine salicylate (0.15 to 0.25 mg/kg). Following pretreatment, the animal was placed in the behavioral box and given fifty trials. At the termination of this session the animal was given either isotonic saline or physostigmine and returned to the behavioral chamber for further testing.

AChE Assay. All animals used in these experiments were sacrificed by decapitation; each brain was quickly excised, split sagitally and the cerebellum dissected away. The left half of the cerebrum was weighed and homogenized in cold saline (141 μM NaCl, 1 : 10), and stored at 4°C until assay, usually within 4 hr after sacrifice. One milliliter of homogenate (the equivalent of 100 mg of brain) was diluted 1 : 30 in distilled water. This mixture was placed in a water bath maintained at 37.5°C and the pH adjusted to 7.4. AChE activity was determined by the pH stat technique (JENSEN-HOLM et al., 1959). A total of 8.3 mg (4.3 × 10⁻⁴ μM/g) acetyl-β-methylcholine chloride (methacholine) was added to the mixture. The acid liberated from methacholine hydrolysis was neutralized and pH maintained at 7.4 with CO₂ free NaOH (0.1 or 0.05 N) by means of an automatic recording titrator (Radiometer, Inc.). Each analysis was followed for 5–10 min after the
Physostigmine and conditioned behavior

Homogenate blank was determined. Cholinesterase activity was calculated from the quantity of NaOH added per unit time and evaluated as $\mu$M of methacholine hydrolyzed/g of brain/sec. Absolute rates were equivalent to enzymatic hydrolysis of methacholine plus its non-enzymatic hydrolysis which, in these studies, was insignificant.

**ACh Assay.** Following decapitation, brain tissue was excised, the cerebellum removed, and the right half of the cerebrum frozen in isopentane contained in a beaker surrounded by ethanol and dry ice. The following day the frozen tissue was weighed and pulverized in a stainless steel mortar cooled in dry ice. Brain extracts were prepared by the acid-alcohol method (Stone, 1955; Crossland, 1961). The ACh-like activity of the extracts was bioassayed on the isolated frog (Rana pipiens) rectus abdominus muscle preparation. Rectus muscles were mounted in a 4 ml assay chamber containing frog-Ringer's solution ($25^\circ$C) and attached to an isotonic lever. Air was bubbled through a sintered glass attachment at the bottom of the muscle bath. A 1.5 g load was placed on the lever to stretch the muscle and neostigmine salicylate (6 mg/l) added to the frog-Ringer's. After a 30-min equilibration period, the load on the lever was reduced to 1.0 g. The isotonic contraction was recorded for 2 min on a smoked paper kymograph. The recorded response represented a 20:1 magnification of muscle contraction. The muscle was washed for 5-10 min between consecutive responses. The wash interval was constant for each muscle preparation. Stock solutions of ACh standards were prepared in frog-Ringer's containing neostigmine. As suggested by Feldberg (1945), ACh standards were prepared in alkali-inactivated extracts to allow for the presence of sensitizing factors in the brain tissue.

All tabulated data were presented as the mean ± S.E. Student $t$-tests for group comparison were performed according to Snedecor (1956).

**RESULTS**

**Effect of physostigmine on conditioned pole jump behavior**

Increasing doses of physostigmine (0.15 to 0.25 mg/kg s.c.) progressively depressed conditioned avoidance behavior in the rat. Avoidance was affected more than escape. In the above dose range, physostigmine also produced symptoms of cholinergic-induced distress. Therefore methyl atropine and (−) hyoscyamine were used as possible antagonists.

The mean data of six overtrained rats given 0.15 mg/kg of physostigmine 30 min after saline solution, methyl atropine and (−) hyoscyamine pretreatments are given in Table 1.

**Table 1. Effects of methyl atropine and (−) hyoscyamine pretreatment on the onset and duration of physostigmine (0.15 mg/kg) induced behavioral depression**

<table>
<thead>
<tr>
<th>Pretreatment</th>
<th>Mean onset of action ± S.E. in min</th>
<th>Mean duration of action ± S.E. in min</th>
<th>Mean % avoidance ± S.E.</th>
<th>Mean % of escape ± S.E.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saline</td>
<td>13.1 ± 1.2</td>
<td>37.3 ± 2.4</td>
<td>12.9 ± 4.4</td>
<td>69.0 ± 5.6</td>
</tr>
<tr>
<td>Atropine methyl nitrate 2.1 mg/kg, s.c.</td>
<td>27.2 ± 1.2</td>
<td>14.6 ± 4.5</td>
<td>32.9 ± 13.7</td>
<td>59.6 ± 14.9</td>
</tr>
<tr>
<td>(−) Hyoscyamine 1.0 mg/kg, s.c.</td>
<td>0</td>
<td>0</td>
<td>97.3 ± 0.7</td>
<td>2.7 ± 0.7</td>
</tr>
</tbody>
</table>

The data show that methyl atropine and (−) hyoscyamine effectively reversed the effects of physostigmine.
The onset of action was recorded as the avoidance behavior became blocked by 50% the duration of action was measured from that moment till the avoidance block became less than 50%. The percent depression of avoidance and escape was calculated during the period of at least 50% depression per block of ten trials. It can be seen that methyl atropine and (-) hyoscyamine, in comparison to saline, alter the effects of physostigmine but (-) hyoscyamine was much more potent. In saline pretreated animals physostigmine caused 12.9% avoidance and 69.0% escape behavior. Methyl atropine clearly had a partial antagonistic action and increased avoidance responses to 32.9%. On the other hand (-) hyoscyamine almost completely antagonized the behavioral effects of physostigmine.

In methyl atropine-pretreated rats, increasing doses of physostigmine produced dose-related depression of avoidance behavior as illustrated in Fig. 1. A dose of 0.25 mg/kg of physostigmine produced maximum inhibition of avoidance behavior. Escape behavior, on the other hand, was relatively unimpaired and therefore not plotted. At maximal behavioral depression, animals escaped 88.0 ± 9.4% of the time, whereas they avoided at a rate of only 2.4 ± 2.0%. Escape behavior was also markedly depressed in doses greater than 0.25 mg/kg. Therefore, larger doses were not studied.

In contrast to results obtained with methyl atropine-pretreated animals, an equimolar dose of (-) hyoscyamine completely antagonized the behavioral depression produced by 0.25 mg/kg of physostigmine. Because of the graded effect obtained with several doses of (-) hyoscyamine, this antagonism appeared to be competitive. This effect is clearly evident in Fig. 2.

**Time course of physostigmine-induced alterations in brain ACh and AChE**

Since 0.25 mg/kg physostigmine was most effective in depressing avoidance behavior in methyl atropine-pretreated animals, this dose was used to determine the temporal relationship between ACh accumulation, AChE inhibition and avoidance behavior (Fig. 3). Sacrifice times were selected to correspond to the onset, maximum and termination of behavioral depression. Both ACh and AChE levels were significantly different (P < 0.05)

![Figure 1: Effects of physostigmine on conditioned pole jumping in rats.](image)
Physostigmine and conditioned behavior

The duration of at least 50 per cent blockade of avoidance behavior was determined between the onset and recovery of 50 per cent avoidance per group of ten trials following physostigmine (0.25 mg/kg). Each bar represents the mean of six animals. The muscarinic blocking drugs were administered 30 min prior to physostigmine.

Each point represents the mean ± S.E. of four separate groups of methyl atropine (2.1 mg/kg) pretreated animals. Control ACh levels = 13.7 ± 1.7 μM/g as acetylcholine chloride and control AChE levels = 86.0 ± 1.9 μM/g/sec.

from controls at the onset of behavioral depression. ACh accumulation and concurrent AChE inhibition occurred within the time of the avoidance depression. The increase in ACh was significant primarily at the onset of behavioral depression, whereas AChE levels were significantly lower than control levels both at the time of the onset of depression and at that of maximal effect of the drug ($P < 0.01$). It is also interesting to note that the induced chemical changes persisted beyond 90 min after injection.
Although (−) hyoscyamine was an effective antagonist of physostigmine-induced behavioral depression it did not significantly modify the alteration of brain ACh and AChE (Fig. 4). With the doses used, neither methyl atropine nor (−) hyoscyamine alone had a significant effect on either brain ACh or depressed conditioned avoidance behavior in these highly overtrained animals.

It was noted that physostigmine produced a dose–effect relationship in the depression of avoidance behavior as well as inhibition of brain AChE. However, there was a clear dissociation between the recovery of behavior and AChE inhibition. Behavioral recovery occurred within 60–90 min after physostigmine. At this time, ACh and AChE levels were still altered 21 to 23% as compared to control. This can be observed in Figs. 1 and 3 for 0.25 mg/kg of physostigmine. A similar dissociation during the recovery period was noted for 0.15 and 0.175 mg/kg of physostigmine as well in other series of animals.

**Dissociation of AChE inhibition and recovery of behavior following physostigmine**

Physostigmine has mixed central and peripheral actions which may influence behavior. In addition to an intended central effect, physostigmine may induce skeletal muscle fasciculations, salivation, lacrimation, urination and diarrhea (SLUD syndrome) although this syndrome was not as evident as we had expected. Nevertheless, the quaternary muscarinic (m)-cholinergic blocking agent methyl atropine was used to reduce these possible peripheral effects. In the doses used, methyl atropine does not have any behavioral effects and no change in brain ACh and AChE was observed. Not all of the peripheral actions of physostigmine are blocked by methyl atropine. For example the peripheral nicotinic (n)-cholinergic actions at the skeletal neuromuscular junction are not antagonized. Our data clearly show that methyl atropine partially antagonizes the depressant effects of physostigmine on avoidance behavior indicating that peripheral cholinergic stimulation impair
Physostigmine and conditioned behavior

The degree of AChE inhibition in vivo and its relationship to behavior requires cautious interpretation. Even though animals avoided at pre-injection rates 60–90 min after physostigmine, brain AChE was only 79% of control. Since these animals were apparently performing normally, one might conclude that AChE must be inhibited by more than 21% before learned behavior is altered. Goldberg et al. (1963) found that cholinesterase activity must be inhibited 25 to 50% to affect avoidance behavior in a similar task. In addition, they observed that avoidance behavior returned before recovery from AChE inhibition.

A large amount of AChE in the brain occurs intraneuronally and may not participate in synaptic function. In correlative in vivo–in vitro studies such as the present, it should be realized that homogenization of brain tissue brings molecules of inhibitor and enzyme into contact which may not have been responsible for the behavioral events occurring immediately prior to brain removal. Thus, the percent of AChE inhibition measured in vitro should be considered as indicative of the total concentration of inhibitor and enzyme in the brain, rather than the actual degree of AChE inhibition in vivo. When AChE inhibition is measured manometrically or titrimetrically, in vitro, following the administration of a "reversible" inhibitor such as physostigmine, homogenization and dilution involved in the procedures cause a reversal of the inhibition. Thus the inhibition recorded probably is less than that which actually occurred. Furthermore, at present there is no method of determining the actual in vivo concentrations of ACh at critical physiological receptor sites. Hopefully, the degree of AChE inhibition and ACh at the receptor site is proportional to the measurements made. Assuming that the data obtained reflect the true state of affairs, one can conclude that the behavioral actions of physostigmine under the conditions of these experiments are indirect, i.e. the result of ACh accumulation at m-cholinergic reception sites. Furthermore, (−) hyoscyamine antagonizes the behavioral depression by competing with ACh at these same central sites. It should be realized we are referring to an ACh-like substance since a nonselective bioassay technique was used. However, numerous investigators have shown that this ACh-like substance has pharmacologic actions and chemical properties similar to ACh (Crossland and Redfern, 1963; McLennan et al., 1963; Pepeu et al., 1963; Szerb, 1963; Ryall et al., 1964; Whittaker and Dowe, 1964; and Stavinoha and Ryan, 1965).

Although the present study suggests that physostigmine acts by preventing ACh destruction, there is the possibility that the drug may act independent of AChE inhibition. It is known, for example, that large doses of physostigmine have a direct blocking action on autonomic ganglia (Paton and Perry, 1953). Recently Bradley (1967) demonstrated an action of physostigmine different from that of ACh on micro-electrophoretic injection on brainstem neurons. Furthermore, physostigmine may release other potential neurotransmitters such as serotonin (Aprison et al., 1962) and catecholamines (Cabrera et al., 1966). The fact that (−) hyoscyamine so effectively antagonizes the behavioral actions of physostigmine seems to rule out a direct role of biogenic amines in its actions.

REFERENCES


